Christina Bahrs
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Christina Bahrs has a total of 368 co-authors. Here are the top co-authors by number of shared publications:
- Mathias Wilhelm Pletz
Institute for Infectious Diseases and Infection Control, Jena University Hospital, 07747 Jena, Germany
26 shared publications - Stefan Hagel
Institute for Infectious Diseases and Infection Control, Jena University Hospital, Jena, Germany
12 shared publications Wolfgang Graninger
Department of Medicine I, Division of Infectious Diseases and Tropical Medicine, Medical University of Vienna, Währinger Gürtel 18–20, 1090, Vienna, Austria
11 shared publications- Nicole Harrison
Division of Infectious Diseases and Tropical Medicine, Department of Medicine I, Medical University of Vienna, Vienna, Austria
10 shared publications - Heinz Burgmann
Clinical Division of Infectious Diseases and Tropical Medicine, Department of Medicine I, Medical University of Vienna, 1090 Vienna, Austria
9 shared publications Bettina Löffler
Institute of Medical Microbiology, Jena University Hospital/Friedrich-Schiller-University, Jena, Germany
8 shared publications
Latest Publications
- Open Access
- 2 November 2026
- Published by Elsevier in SSRN Electronic Journal
Symptom Burden, Autoantibodies and T Cell Reactivity After SARS-CoV-2 Infection: Findings from the McPoC Study
Background: Course and cause of persistent symptoms after SARS-CoV-2 infection, often termed post-COVID syndrome, remain poorly understood. In this prospective cohort study with access to pre-infection blood samples, we aimed to analyze functional and immunological correlates of symptom burden, focusing on autoantibodies against G-protein-coupled receptors (GPCRs) among hospital staff with and without previous SARS-CoV-2 infection.Methods: Participants of the Jena Co-HCW study were recontacted in May/June 2022 to assess potential post-COVID symptom burden and autoantibodies using questionnaires (PHQ-9, BFI, FAS), cognitive and physical tests (MoCA, 1-minute sit-to-stand [1-STS], handgrip strength), and immunological assays including ELISpot and autoantibody profiling. SARS-CoV-2 infection status was determined by nucleocapsid antibody testing; symptom severity was categorized as mild/none vs. moderate/severe.Results: Of 579 individuals screened, 131 hospital employees (22.6%) participated in the McPoC study (mean age: 44.2 ± 9.5 years, 79.4% female, COVID-19 vaccination status: 97.7%). Among the 78 individuals with previous SARS-CoV-2 infection (CoV+), 32 (41.0%) reported experiencing either newly developed or persistent symptoms, with moderate to severe intensity in 26 cases (33.3%). Participants with moderate to severe symptoms (n = 41) showed significantly higher PHQ-9 (mean difference = 1.38, p = 0.009), BFI (mean difference = 1.04, p < 0.0001), and FAS (mean difference = 3.0, p = 0.002) scores than those with no or only mild symptoms (n = 89). Trends toward reduced handgrip strength and 1-STS performance were observed, though not significant. GPCR autoantibodies were highly prevalent (e.g. β2-AR: 63.4%; M3-AChR: 82.4%) but not associated with symptom severity or test outcomes. IFN-γ responses to PAN-coronavirus peptides were more frequent in CoV+ compared to CoV- individuals (37% vs 15%, p = 0.009); a non-significant trend toward lower IFN-γ reactivity to SARS-CoV-2 peptides was found in more symptomatic individuals (34% vs 52.5%, p = 0.082).Conclusions: Functional and psychological impairments were more strongly linked to symptom severity than infection status. Despite high seroprevalence of GPCR autoantibodies, their clinical relevance remains uncertain.
- 2 November 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessSymptom Burden, Autoantibodies and T Cell Reactivity After SARS-CoV-2 Infection: Findings from the McPoC Study
Background: Course and cause of persistent symptoms after SARS-CoV-2 infection, often termed post-COVID syndrome, remain poorly understood. In this prospective cohort study with access to pre-infection blood samples, we aimed to analyze functional and immunological correlates of symptom burden, focusing on autoantibodies against G-protein-coupled receptors (GPCRs) among hospital staff with and without previous SARS-CoV-2 infection.Methods: Participants of the Jena Co-HCW study were recontacted in May/June 2022 to assess potential post-COVID symptom burden and autoantibodies using questionnaires (PHQ-9, BFI, FAS), cognitive and physical tests (MoCA, 1-minute sit-to-stand [1-STS], handgrip strength), and immunological assays including ELISpot and autoantibody profiling. SARS-CoV-2 infection status was determined by nucleocapsid antibody testing; symptom severity was categorized as mild/none vs. moderate/severe.Results: Of 579 individuals screened, 131 hospital employees (22.6%) participated in the McPoC study (mean age: 44.2 ± 9.5 years, 79.4% female, COVID-19 vaccination status: 97.7%). Among the 78 individuals with previous SARS-CoV-2 infection (CoV+), 32 (41.0%) reported experiencing either newly developed or persistent symptoms, with moderate to severe intensity in 26 cases (33.3%). Participants with moderate to severe symptoms (n = 41) showed significantly higher PHQ-9 (mean difference = 1.38, p = 0.009), BFI (mean difference = 1.04, p < 0.0001), and FAS (mean difference = 3.0, p = 0.002) scores than those with no or only mild symptoms (n = 89). Trends toward reduced handgrip strength and 1-STS performance were observed, though not significant. GPCR autoantibodies were highly prevalent (e.g. β2-AR: 63.4%; M3-AChR: 82.4%) but not associated with symptom severity or test outcomes. IFN-γ responses to PAN-coronavirus peptides were more frequent in CoV+ compared to CoV- individuals (37% vs 15%, p = 0.009); a non-significant trend toward lower IFN-γ reactivity to SARS-CoV-2 peptides was found in more symptomatic individuals (34% vs 52.5%, p = 0.082).Conclusions: Functional and psychological impairments were more strongly linked to symptom severity than infection status. Despite high seroprevalence of GPCR autoantibodies, their clinical relevance remains uncertain.
- Open Access
- 1 January 2026
- Published by Wiley in Transboundary and Emerging Diseases
- Vol. 2026 (1)
Clinical Outcomes of Penicillin‐Based Therapy Compared to Alternative Enterococcal Treatment in Patients With Vancomycin‐Susceptible Enterococcal Bloodstream Infections: A Monocentric Cohort Study
The aim of this retrospective cohort study was to evaluate clinical outcomes of penicillin‐based therapies (ampicillin, ampicillin/sulbactam, or piperacillin/tazobactam) compared with alternative therapies (glycopeptides, linezolid, or daptomycin) in patients with vancomycin‐susceptible enterococcal bloodstream infections (BSIs). Adult patients with a positive blood culture (BC) for a vancomycin‐susceptible Enterococcus species were screened from January 2017 to December 2018. Patients who received adequate antibiotic therapy for at least 48 h were enrolled. The primary outcome, 30‐day mortality, was compared between patients receiving penicillin‐based and those receiving alternative therapies using the Fisher exact test. Secondary outcomes included 90‐day mortality, relapse BSI, length of hospital stay (LOS), and potential antibiotic‐related adverse events. To identify independent predictors of 30‐day mortality, multivariable logistic regression analysis was weighted for ampicillin susceptibility using propensity scores. Of the 150 patients screened, 127 (84.6%) were included in the final analysis. Among them, 36 (28.3%) developed a septic shock. Aminopenicillin‐susceptible Enterococcus species (mainly E. faecalis ) accounted for 59.1% of bacteremia cases. Sixty‐seven (52.1%) patients received a penicillin‐based regimen (monotherapy n = 48, combination n = 19), and 60 (47.2%) patients received an alternative regimen. Patients receiving penicillin‐based therapy exhibited a lower 30‐day mortality rate of 13.4% compared to 40% ( p = 0.001) in those receiving alternative treatments. The 90‐day mortality rates were reduced (13.4% versus 41.7%), and LOS was shorter (median 21 versus 35 days) for patients with penicillin‐based therapy. There was no significant difference in relapse BSI or potential adverse events between the groups ( p > 0.05). However, in the multivariable weighted regression model, only septic shock (aOR with 95% CI: 23.53 [1.66; 334.54]) was identified as an independent positive predictor of 30‐day mortality. In conclusion, penicillin‐based therapy was still an effective and safe treatment but was not associated with an improved survival in a weighted analysis of patients with enterococcal BSI.
- 1 January 2026
- Published by Wiley in Transboundary and Emerging Diseases
- Vol. 2026 (1)
Open AccessClinical Outcomes of Penicillin‐Based Therapy Compared to Alternative Enterococcal Treatment in Patients With Vancomycin‐Susceptible Enterococcal Bloodstream Infections: A Monocentric Cohort Study
The aim of this retrospective cohort study was to evaluate clinical outcomes of penicillin‐based therapies (ampicillin, ampicillin/sulbactam, or piperacillin/tazobactam) compared with alternative therapies (glycopeptides, linezolid, or daptomycin) in patients with vancomycin‐susceptible enterococcal bloodstream infections (BSIs). Adult patients with a positive blood culture (BC) for a vancomycin‐susceptible Enterococcus species were screened from January 2017 to December 2018. Patients who received adequate antibiotic therapy for at least 48 h were enrolled. The primary outcome, 30‐day mortality, was compared between patients receiving penicillin‐based and those receiving alternative therapies using the Fisher exact test. Secondary outcomes included 90‐day mortality, relapse BSI, length of hospital stay (LOS), and potential antibiotic‐related adverse events. To identify independent predictors of 30‐day mortality, multivariable logistic regression analysis was weighted for ampicillin susceptibility using propensity scores. Of the 150 patients screened, 127 (84.6%) were included in the final analysis. Among them, 36 (28.3%) developed a septic shock. Aminopenicillin‐susceptible Enterococcus species (mainly E. faecalis ) accounted for 59.1% of bacteremia cases. Sixty‐seven (52.1%) patients received a penicillin‐based regimen (monotherapy n = 48, combination n = 19), and 60 (47.2%) patients received an alternative regimen. Patients receiving penicillin‐based therapy exhibited a lower 30‐day mortality rate of 13.4% compared to 40% ( p = 0.001) in those receiving alternative treatments. The 90‐day mortality rates were reduced (13.4% versus 41.7%), and LOS was shorter (median 21 versus 35 days) for patients with penicillin‐based therapy. There was no significant difference in relapse BSI or potential adverse events between the groups ( p > 0.05). However, in the multivariable weighted regression model, only septic shock (aOR with 95% CI: 23.53 [1.66; 334.54]) was identified as an independent positive predictor of 30‐day mortality. In conclusion, penicillin‐based therapy was still an effective and safe treatment but was not associated with an improved survival in a weighted analysis of patients with enterococcal BSI.
- Open Access
Pneumococcal pneumonia in adults – Re-emergence of vaccine serotypes: a prospective multicentre cohort study in Germany, 2020-2023
This prospective multicentre study investigated pneumococcal serotype distribution and vaccine coverage of the 13- and 20-valent conjugate vaccines, and the 23-valent polysaccharide vaccine among adults with community-acquired pneumonia in Germany, from 2020 to 2023, using serotype-specific urine antigen detection testing. The findings show that Streptococcus pneumoniae has reemerged as causative pathogen of pneumonia, particularly in adults aged ≥60 years. This resurgence, observed during the ongoing SARS-CoV-2 pandemic, has been primarily driven by an increase in cases due to serotype 3.
Open AccessPneumococcal pneumonia in adults – Re-emergence of vaccine serotypes: a prospective multicentre cohort study in Germany, 2020-2023
This prospective multicentre study investigated pneumococcal serotype distribution and vaccine coverage of the 13- and 20-valent conjugate vaccines, and the 23-valent polysaccharide vaccine among adults with community-acquired pneumonia in Germany, from 2020 to 2023, using serotype-specific urine antigen detection testing. The findings show that Streptococcus pneumoniae has reemerged as causative pathogen of pneumonia, particularly in adults aged ≥60 years. This resurgence, observed during the ongoing SARS-CoV-2 pandemic, has been primarily driven by an increase in cases due to serotype 3.
- Open Access
- 20 July 2024
- Published by Springer Nature in Infection
- Vol. 53 (1) , 449-455
Frequency and clinical significance of Herpes simplex virus type 1/2 reactivation in adult patients with mild to moderately severe community-acquired pneumonia: a multicentre cohort study
Purpose: This study assessed the frequency, clinical significance, and risk factors for Herpes simplex virus (HSV) reactivation in immunocompetent patients with community-acquired pneumonia (CAP). Methods: The study included adult CAP-patients who were enrolled in the CAPNETZ study between 2007 and 2017 and had a residual sputum sample available for analysis. In addition to routine diagnostics, sputum and blood samples were tested for HSV-1/2 using PCR. Demographics, comorbidities, and CRB-65 score were compared between HSV-positive and negative patients using Fisher exact or Mann Whitney test. Logistic regression analyses investigated the influence of HSV reactivation on a modified hospital recovery scale (HRS) until day 7, divided into 3 categories (no oxygen therapy, oxygen therapy, ICU admission or death). Results: Among 245 patients, HSV-1 and HSV-2 were detected in 30 patients (12.2%, 95%CI 8.7–16.9) and 0 patients, respectively. All HSV-positive patients were hospitalized, had a CRB-65 severity score of 0–2 and survived the first 28 day. In the HSV-positive group, patients had a non-significantly higher median age (70.5 versus 66 years) and a higher rate of oncological comorbidities (16.7% versus 8.8%) compared to the HSV-negative group. Distribution of co-pathogens and outcome parameters did not significantly differ between both groups. In a multivariate logistic regression model, age (AOR 1.029, p = 0.012) and CRB-65 score (AOR 1.709, p = 0.048), but not HSV-1 as single or co-pathogen were independently associated with higher HRS. Conclusion: Our study suggests that HSV-1 reactivation is common in CAP but might not be associated with specific risk factors or a complicated disease course.
- 20 July 2024
- Published by Springer Nature in Infection
- Vol. 53 (1) , 449-455
Open AccessFrequency and clinical significance of Herpes simplex virus type 1/2 reactivation in adult patients with mild to moderately severe community-acquired pneumonia: a multicentre cohort study
Purpose: This study assessed the frequency, clinical significance, and risk factors for Herpes simplex virus (HSV) reactivation in immunocompetent patients with community-acquired pneumonia (CAP). Methods: The study included adult CAP-patients who were enrolled in the CAPNETZ study between 2007 and 2017 and had a residual sputum sample available for analysis. In addition to routine diagnostics, sputum and blood samples were tested for HSV-1/2 using PCR. Demographics, comorbidities, and CRB-65 score were compared between HSV-positive and negative patients using Fisher exact or Mann Whitney test. Logistic regression analyses investigated the influence of HSV reactivation on a modified hospital recovery scale (HRS) until day 7, divided into 3 categories (no oxygen therapy, oxygen therapy, ICU admission or death). Results: Among 245 patients, HSV-1 and HSV-2 were detected in 30 patients (12.2%, 95%CI 8.7–16.9) and 0 patients, respectively. All HSV-positive patients were hospitalized, had a CRB-65 severity score of 0–2 and survived the first 28 day. In the HSV-positive group, patients had a non-significantly higher median age (70.5 versus 66 years) and a higher rate of oncological comorbidities (16.7% versus 8.8%) compared to the HSV-negative group. Distribution of co-pathogens and outcome parameters did not significantly differ between both groups. In a multivariate logistic regression model, age (AOR 1.029, p = 0.012) and CRB-65 score (AOR 1.709, p = 0.048), but not HSV-1 as single or co-pathogen were independently associated with higher HRS. Conclusion: Our study suggests that HSV-1 reactivation is common in CAP but might not be associated with specific risk factors or a complicated disease course.
- 10 August 2023
- Published by Springer Nature in Die Innere Medizin
- Vol. 64 (9) , 907-910
Impfung gegen das „respiratory syncytial virus“
- 10 August 2023
- Published by Springer Nature in Die Innere Medizin
- Vol. 64 (9) , 907-910
Impfung gegen das „respiratory syncytial virus“
- Open Access
- 18 July 2023
- Published by Springer Nature in Infection
- Vol. 51 (6) , 1749-1758
Early treatment response to piperacillin/tazobactam in patients with bloodstream infections caused by non-ESBL ampicillin/sulbactam-resistant Escherichia coli: a binational cohort study
Purpose: This study aimed to compare treatment outcomes for bloodstream infections (BSI) caused by a piperacillin/tazobactam (PIP/TAZ)-susceptible E. coli among three patient groups: BSI caused by ampicillin/sulbactam (AMP/SLB)-resistant isolates treated with PIP/TAZ, BSI caused by AMP/SLB-sensitive isolates treated with PIP/TAZ, and BSI caused by AMP/SLB-resistant isolates treated with another monotherapy. Methods: This retrospective study was conducted in two academic centres in Europe. Adult patients with E. coli BSI were screened from 2014 to 2020. Inclusion criteria were non-ESBL BSI and initial monotherapy for ≥ 72 h. To reduce the expected bias between the patient groups, propensity score matching was performed. The primary outcome was early treatment response after 72 h and required absence of SOFA score increase in ICU/IMC patients, as well as resolution of fever, leukocytosis, and bacteraemia. Results: Of the 1707 patients screened, 315 (18.5%) were included in the final analysis. Urinary tract infection was the most common source of BSI (54.9%). Monotherapies other than PIP/TAZ were cephalosporins (48.6%), carbapenems (34.3%), and quinolones (17.1%). Enhanced early treatment response rate was detected (p = 0.04) in patients with BSI caused by AMP/SLB-resistant isolates treated with another monotherapy (74.3%) compared to those treated with PIP/TAZ (57.1%), and was mainly driven by the use of cephalosporins and quinolones (p ≤ 0.03). Clinical success, 28-day mortality, and rate of relapsing BSI did not significantly differ between the groups. Conclusions: Our study suggests that initial use of PIP/TAZ may be associated with reduced early treatment response in E. coli BSI caused by AMP/SLB-resistant isolates compared to alternative monotherapies.
- 18 July 2023
- Published by Springer Nature in Infection
- Vol. 51 (6) , 1749-1758
Open AccessEarly treatment response to piperacillin/tazobactam in patients with bloodstream infections caused by non-ESBL ampicillin/sulbactam-resistant Escherichia coli: a binational cohort study
Purpose: This study aimed to compare treatment outcomes for bloodstream infections (BSI) caused by a piperacillin/tazobactam (PIP/TAZ)-susceptible E. coli among three patient groups: BSI caused by ampicillin/sulbactam (AMP/SLB)-resistant isolates treated with PIP/TAZ, BSI caused by AMP/SLB-sensitive isolates treated with PIP/TAZ, and BSI caused by AMP/SLB-resistant isolates treated with another monotherapy. Methods: This retrospective study was conducted in two academic centres in Europe. Adult patients with E. coli BSI were screened from 2014 to 2020. Inclusion criteria were non-ESBL BSI and initial monotherapy for ≥ 72 h. To reduce the expected bias between the patient groups, propensity score matching was performed. The primary outcome was early treatment response after 72 h and required absence of SOFA score increase in ICU/IMC patients, as well as resolution of fever, leukocytosis, and bacteraemia. Results: Of the 1707 patients screened, 315 (18.5%) were included in the final analysis. Urinary tract infection was the most common source of BSI (54.9%). Monotherapies other than PIP/TAZ were cephalosporins (48.6%), carbapenems (34.3%), and quinolones (17.1%). Enhanced early treatment response rate was detected (p = 0.04) in patients with BSI caused by AMP/SLB-resistant isolates treated with another monotherapy (74.3%) compared to those treated with PIP/TAZ (57.1%), and was mainly driven by the use of cephalosporins and quinolones (p ≤ 0.03). Clinical success, 28-day mortality, and rate of relapsing BSI did not significantly differ between the groups. Conclusions: Our study suggests that initial use of PIP/TAZ may be associated with reduced early treatment response in E. coli BSI caused by AMP/SLB-resistant isolates compared to alternative monotherapies.
- Open Access
- 15 February 2023
- Published by Springer Nature in Infection
- Vol. 51 (4) , 1051-1059
Non-patient-related SARS-CoV-2 exposure from colleagues and household members poses the highest infection risk for hospital employees in a German university hospital: follow-up of the prospective Co-HCW seroprevalence study
Purpose: The Co-HCW study is a prospective, longitudinal, single-center observational study that aims to assess the SARS-CoV-2 seroprevalence and infection status in staff members of Jena University Hospital (JUH) in Jena, Germany. Methods: This follow-up study covers the observation period from 19th May 2020 to 22nd June 2021. At each of the three voluntary study visits, participants filled out a questionnaire regarding their SARS-CoV-2 exposure and provided serum samples to detect specific SARS-CoV-2 antibodies. Participants who were tested positive for antibodies against nucleocapsid and/or spike protein without previous vaccination and/or reported a positive SARS-CoV-2 PCR test were regarded to have been infected with SARS-CoV-2. Multivariable logistic regression modeling was applied to identify potential risk factors for infected compared to non-infected participants. Results: Out of 660 participants that were included during the first study visit, 406 participants (61.5%) were eligible for the final analysis as their COVID-19 risk area (high-risk n = 76; intermediate-risk n = 198; low-risk n = 132) did not change during the study. Forty-four participants [10.8%, 95% confidence interval (95%CI) 8.0–14.3%] had evidence of a current or past SARS-CoV-2 infection detected by serology (n = 40) and/or PCR (n = 28). No association between SARS-CoV-2 infection and the COVID-19 risk group according to working place was detected. However, exposure to a SARS-CoV-2 positive household member [adjusted OR (AOR) 4.46, 95% CI 2.06–9.65] or colleague (AOR 2.30, 95%CI 1.10–4.79) was found to significantly increase the risk of a SARS-CoV-2 infection. Conclusion: Our results demonstrate that non-patient-related SARS-CoV-2 exposure posed the highest infection risk for hospital staff members of JUH.
- 15 February 2023
- Published by Springer Nature in Infection
- Vol. 51 (4) , 1051-1059
Open AccessNon-patient-related SARS-CoV-2 exposure from colleagues and household members poses the highest infection risk for hospital employees in a German university hospital: follow-up of the prospective Co-HCW seroprevalence study
Purpose: The Co-HCW study is a prospective, longitudinal, single-center observational study that aims to assess the SARS-CoV-2 seroprevalence and infection status in staff members of Jena University Hospital (JUH) in Jena, Germany. Methods: This follow-up study covers the observation period from 19th May 2020 to 22nd June 2021. At each of the three voluntary study visits, participants filled out a questionnaire regarding their SARS-CoV-2 exposure and provided serum samples to detect specific SARS-CoV-2 antibodies. Participants who were tested positive for antibodies against nucleocapsid and/or spike protein without previous vaccination and/or reported a positive SARS-CoV-2 PCR test were regarded to have been infected with SARS-CoV-2. Multivariable logistic regression modeling was applied to identify potential risk factors for infected compared to non-infected participants. Results: Out of 660 participants that were included during the first study visit, 406 participants (61.5%) were eligible for the final analysis as their COVID-19 risk area (high-risk n = 76; intermediate-risk n = 198; low-risk n = 132) did not change during the study. Forty-four participants [10.8%, 95% confidence interval (95%CI) 8.0–14.3%] had evidence of a current or past SARS-CoV-2 infection detected by serology (n = 40) and/or PCR (n = 28). No association between SARS-CoV-2 infection and the COVID-19 risk group according to working place was detected. However, exposure to a SARS-CoV-2 positive household member [adjusted OR (AOR) 4.46, 95% CI 2.06–9.65] or colleague (AOR 2.30, 95%CI 1.10–4.79) was found to significantly increase the risk of a SARS-CoV-2 infection. Conclusion: Our results demonstrate that non-patient-related SARS-CoV-2 exposure posed the highest infection risk for hospital staff members of JUH.
- Open Access
Non-patient related SARS-CoV-2 exposure to colleagues and household members impose the highest infection risk for hospital employees with and without patient contact in a German university hospital: follow-up of the prospective Co-HCW Seroprevalence study
Background: The Co-HCW study is a prospective, longitudinal single center observational study on the SARS-CoV-2 seroprevalence and infection status in staff members of Jena University Hospital (JUH) in Jena, Germany. Material and Methods: This follow-up study covers the observation period from 19 th May 2020 to 22 nd June 2021. At each out of three voluntary study visits, participants filled out a questionnaire on individual SARS-CoV-2 exposure. In addition, serum samples to assess specific SARS-CoV-2 antibodies were collected. Participants with antibodies against nucleocapsid and/or spike protein without previous vaccination and/or a reported positive SARS-CoV-2 PCR test were regarded as participants with detected SARS-CoV-2 infection. Multivariable logistic regression modeling was applied to identify potential risk factors for infected compared to non-infected participants. Results: Out of 660 participants that were included during the first study visit, 406 participants (61.5%) were eligible for final analysis as they did not change the COVID-19 risk area (high-risk n=76; intermediate-risk n=198; low-risk n=132) during the study. Forty-four participants (10.8%, 95% confidence interval (95%CI) 8.0%-14.3%) had evidence of a current or past SARS-CoV-2 infection detected by serology (n=40) and/or PCR (n=28). No association of any SARS-CoV-2 infection with the COVID-19 risk group according to working place could be detected. But exposure to a SARS-CoV-2 positive household member (adjusted OR (AOR) 4.46, 95%CI 2.06-9.65) or colleague (AOR 2.30, 95%CI 1.10-4.79) significantly increased the risk of a SARS-CoV-2 infection. Conclusion: Our results demonstrate that non-patient-related SARS-CoV-2 exposure imposed the highest infection risk in hospital staff members of JUH.
Open AccessNon-patient related SARS-CoV-2 exposure to colleagues and household members impose the highest infection risk for hospital employees with and without patient contact in a German university hospital: follow-up of the prospective Co-HCW Seroprevalence study
Background: The Co-HCW study is a prospective, longitudinal single center observational study on the SARS-CoV-2 seroprevalence and infection status in staff members of Jena University Hospital (JUH) in Jena, Germany. Material and Methods: This follow-up study covers the observation period from 19 th May 2020 to 22 nd June 2021. At each out of three voluntary study visits, participants filled out a questionnaire on individual SARS-CoV-2 exposure. In addition, serum samples to assess specific SARS-CoV-2 antibodies were collected. Participants with antibodies against nucleocapsid and/or spike protein without previous vaccination and/or a reported positive SARS-CoV-2 PCR test were regarded as participants with detected SARS-CoV-2 infection. Multivariable logistic regression modeling was applied to identify potential risk factors for infected compared to non-infected participants. Results: Out of 660 participants that were included during the first study visit, 406 participants (61.5%) were eligible for final analysis as they did not change the COVID-19 risk area (high-risk n=76; intermediate-risk n=198; low-risk n=132) during the study. Forty-four participants (10.8%, 95% confidence interval (95%CI) 8.0%-14.3%) had evidence of a current or past SARS-CoV-2 infection detected by serology (n=40) and/or PCR (n=28). No association of any SARS-CoV-2 infection with the COVID-19 risk group according to working place could be detected. But exposure to a SARS-CoV-2 positive household member (adjusted OR (AOR) 4.46, 95%CI 2.06-9.65) or colleague (AOR 2.30, 95%CI 1.10-4.79) significantly increased the risk of a SARS-CoV-2 infection. Conclusion: Our results demonstrate that non-patient-related SARS-CoV-2 exposure imposed the highest infection risk in hospital staff members of JUH.
- 26 September 2022
- Published by Springer Nature in Zeitschrift für Pneumologie
- Vol. 19 (6) , 359-368
Antibiotic Stewardship und Pneumonie
Zusammenfassung Die Pneumonie ist eine sehr häufige und potenziell tödliche Erkrankung. Es werden 3 Entitäten (ambulant erworbenen = CAP, nosokomial erworben = HAP und Pneumonie unter Immunsuppression) unterschieden von denen insbesondere die CAP und die HAP für die Umsetzung von Antibiotic Stewardship(ABS)-Strategien, den rationalen Umgang mit Antibiotika, gut geeignet sind. Die Durchführung einer mikrobiologischen Diagnostik vor Start einer Antibiotikatherapie bei Pneumonie, die stationär behandelt werden muss, wird stark empfohlen. Eine Risikostratifizierung der Patienten und der Schweregrad der Erkrankung sind entscheidend für die kalkulierte Antibiotikaauswahl und die Applikationsform. Bei COVID-19-Patienten ohne septischen Schock kann aufgrund der niedrigen Rate von bakteriellen Superinfektionen auf eine empirische Antibiotikatherapie verzichtet werden. Eine Reevaluation der Antibiotikatherapie nach 48–72 h mit gezielter Deeskalation unter Beachtung der Klinik und Mikrobiologie, Absetzen bei Fehlindikation und die Begrenzung der Therapiedauer sind essenzielle ABS-Strategien zur Optimierung des klinischen Outcomes bei CAP und HAP mit dem Ziel, die Antibiotikaresistenzentwicklung sowie die Toxizität für den Patienten möglichst gering zu halten. Der Einsatz von Biomarkern wie Procalcitonin kann in bestimmten Situationen ein frühzeitiges Absetzen der Therapie begünstigen oder die Diagnose einer bakteriellen Superinfektion bei COVID-19 unterstützen.
- 26 September 2022
- Published by Springer Nature in Zeitschrift für Pneumologie
- Vol. 19 (6) , 359-368
Antibiotic Stewardship und Pneumonie
Zusammenfassung Die Pneumonie ist eine sehr häufige und potenziell tödliche Erkrankung. Es werden 3 Entitäten (ambulant erworbenen = CAP, nosokomial erworben = HAP und Pneumonie unter Immunsuppression) unterschieden von denen insbesondere die CAP und die HAP für die Umsetzung von Antibiotic Stewardship(ABS)-Strategien, den rationalen Umgang mit Antibiotika, gut geeignet sind. Die Durchführung einer mikrobiologischen Diagnostik vor Start einer Antibiotikatherapie bei Pneumonie, die stationär behandelt werden muss, wird stark empfohlen. Eine Risikostratifizierung der Patienten und der Schweregrad der Erkrankung sind entscheidend für die kalkulierte Antibiotikaauswahl und die Applikationsform. Bei COVID-19-Patienten ohne septischen Schock kann aufgrund der niedrigen Rate von bakteriellen Superinfektionen auf eine empirische Antibiotikatherapie verzichtet werden. Eine Reevaluation der Antibiotikatherapie nach 48–72 h mit gezielter Deeskalation unter Beachtung der Klinik und Mikrobiologie, Absetzen bei Fehlindikation und die Begrenzung der Therapiedauer sind essenzielle ABS-Strategien zur Optimierung des klinischen Outcomes bei CAP und HAP mit dem Ziel, die Antibiotikaresistenzentwicklung sowie die Toxizität für den Patienten möglichst gering zu halten. Der Einsatz von Biomarkern wie Procalcitonin kann in bestimmten Situationen ein frühzeitiges Absetzen der Therapie begünstigen oder die Diagnose einer bakteriellen Superinfektion bei COVID-19 unterstützen.
- 7 September 2022
- Published by Elsevier in Clinical Microbiology and Infection
- Vol. 29 (2) , 200-207
Short-course versus long-course antibiotic treatment for uncomplicated vancomycin-resistant enterococcal bacteraemia: a retrospective multicentre cohort study
- 7 September 2022
- Published by Elsevier in Clinical Microbiology and Infection
- Vol. 29 (2) , 200-207
Short-course versus long-course antibiotic treatment for uncomplicated vancomycin-resistant enterococcal bacteraemia: a retrospective multicentre cohort study